DK1333810T3 - Orale selvemulgerende doseringsformuleringer af pyranon-protease-inhibitorer - Google Patents

Orale selvemulgerende doseringsformuleringer af pyranon-protease-inhibitorer

Info

Publication number
DK1333810T3
DK1333810T3 DK01991175T DK01991175T DK1333810T3 DK 1333810 T3 DK1333810 T3 DK 1333810T3 DK 01991175 T DK01991175 T DK 01991175T DK 01991175 T DK01991175 T DK 01991175T DK 1333810 T3 DK1333810 T3 DK 1333810T3
Authority
DK
Denmark
Prior art keywords
protease inhibitors
pyranone protease
dosage formulations
oral self
emulsifying dosage
Prior art date
Application number
DK01991175T
Other languages
Danish (da)
English (en)
Inventor
Shirlynn Chen
Jocelyn A Gunn
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of DK1333810T3 publication Critical patent/DK1333810T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
DK01991175T 2000-10-31 2001-10-30 Orale selvemulgerende doseringsformuleringer af pyranon-protease-inhibitorer DK1333810T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24443400P 2000-10-31 2000-10-31
PCT/US2001/048683 WO2002036110A2 (en) 2000-10-31 2001-10-30 Oral self-emulsifying formulations of pyranone protease inhibitors

Publications (1)

Publication Number Publication Date
DK1333810T3 true DK1333810T3 (da) 2008-02-04

Family

ID=22922748

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01991175T DK1333810T3 (da) 2000-10-31 2001-10-30 Orale selvemulgerende doseringsformuleringer af pyranon-protease-inhibitorer

Country Status (30)

Country Link
US (1) US6555558B2 (zh)
EP (1) EP1333810B1 (zh)
JP (1) JP4298998B2 (zh)
KR (1) KR100847679B1 (zh)
CN (1) CN1240437C (zh)
AT (1) ATE381922T1 (zh)
AU (2) AU3091802A (zh)
BG (1) BG107728A (zh)
BR (1) BR0114969A (zh)
CA (1) CA2424596C (zh)
CZ (1) CZ20031407A3 (zh)
DE (1) DE60132103T2 (zh)
DK (1) DK1333810T3 (zh)
EA (1) EA006759B1 (zh)
EC (1) ECSP034572A (zh)
EE (1) EE200300201A (zh)
ES (1) ES2298286T3 (zh)
HK (1) HK1060523A1 (zh)
HR (1) HRP20030339A2 (zh)
HU (1) HUP0301487A2 (zh)
IL (2) IL154983A0 (zh)
MX (1) MXPA03003795A (zh)
NO (1) NO20031909L (zh)
NZ (1) NZ526169A (zh)
PL (1) PL365627A1 (zh)
SK (1) SK6572003A3 (zh)
UA (1) UA78689C2 (zh)
WO (1) WO2002036110A2 (zh)
YU (1) YU32103A (zh)
ZA (1) ZA200302389B (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1708680A2 (en) * 2004-01-21 2006-10-11 Janssen Pharmaceutica N.V. Mitratapide oral solution
US20050256097A1 (en) * 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
JP4373427B2 (ja) * 2005-11-15 2009-11-25 エフ．ホフマン−ラ ロシュ アーゲー 電気的滴下監視
EP1957053A4 (en) * 2005-11-17 2012-03-28 Bioavailability Inc BIOKOMPATIBLE LATENT EMULSIFICATORS
EP2037897B1 (en) * 2006-07-06 2011-03-30 Ares Trading S.A. An oral pharmaceutical composition of an anilinopyrimidine, its preparation and use thereof
JP2010526848A (ja) * 2007-05-11 2010-08-05 エフ．ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
CA2687630A1 (en) * 2007-05-23 2008-11-27 Boehringer Ingelheim International Gmbh Self-emulsifying formulation of tipranavir for oral administration
WO2009084036A2 (en) * 2007-12-20 2009-07-09 Matrix Laboratories Limited Composition for treatment of viral infections
WO2012010942A2 (en) * 2010-07-22 2012-01-26 Lupin Limited Novel pharmaceutical composition(s) of hiv protease inhibitor(s)
MY158809A (en) * 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
US20130302414A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
UA116004C2 (uk) 2013-01-22 2018-01-25 Ф. Хоффманн-Ля Рош Аг Фармацевтична композиція з покращеною біодоступністю
US20160000799A1 (en) 2013-02-21 2016-01-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
CA2987272C (en) 2015-05-28 2019-08-20 Dr. Reddy's Laboratories Ltd. Oral composition of celecoxib for treatment of pain
SI3432916T1 (sl) 2016-09-13 2020-01-31 Allergan, Inc. Stabilizirani ne-protein klostridijski toksin sestavki

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE398448T1 (de) * 1993-09-28 2008-07-15 Scherer Gmbh R P Herstellung von weichgelatinekapseln
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
KR0167613B1 (ko) * 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
SK284616B6 (sk) * 1997-07-29 2005-07-01 Pharmacia & Upjohn Company Farmaceutická kompozícia pre kyslé lipofilné zlúčeniny vo forme samoemulgujúcej formulácie
SI0999838T1 (en) * 1997-07-29 2002-08-31 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
CN1154491C (zh) * 1998-11-04 2004-06-23 法玛西雅厄普约翰美国公司 用于改善替普拉那维的药物动力学的方法

Also Published As

Publication number Publication date
HRP20030339A2 (en) 2005-04-30
US6555558B2 (en) 2003-04-29
IL154983A (en) 2006-12-31
DE60132103D1 (de) 2008-02-07
EA006759B1 (ru) 2006-04-28
EE200300201A (et) 2003-08-15
CA2424596A1 (en) 2002-05-10
ATE381922T1 (de) 2008-01-15
ZA200302389B (en) 2004-04-23
ECSP034572A (es) 2003-05-26
SK6572003A3 (en) 2003-10-07
EP1333810B1 (en) 2007-12-26
WO2002036110A2 (en) 2002-05-10
BR0114969A (pt) 2003-12-09
IL154983A0 (en) 2003-10-31
NO20031909L (no) 2003-05-22
DE60132103T2 (de) 2008-04-17
HK1060523A1 (en) 2004-08-13
CN1471387A (zh) 2004-01-28
NO20031909D0 (no) 2003-04-29
PL365627A1 (en) 2005-01-10
ES2298286T3 (es) 2008-05-16
UA78689C2 (en) 2007-04-25
YU32103A (sh) 2006-05-25
CA2424596C (en) 2010-06-29
NZ526169A (en) 2005-12-23
WO2002036110A9 (en) 2003-09-18
HUP0301487A2 (hu) 2003-11-28
EA200300481A1 (ru) 2003-10-30
WO2002036110A3 (en) 2003-05-08
US20020115690A1 (en) 2002-08-22
JP4298998B2 (ja) 2009-07-22
MXPA03003795A (es) 2003-08-20
AU2002230918B2 (en) 2006-12-14
CZ20031407A3 (cs) 2003-09-17
BG107728A (bg) 2004-01-30
KR100847679B1 (ko) 2008-07-23
KR20030048097A (ko) 2003-06-18
CN1240437C (zh) 2006-02-08
JP2004512362A (ja) 2004-04-22
EP1333810A2 (en) 2003-08-13
AU3091802A (en) 2002-05-15

Similar Documents

Publication Publication Date Title
DK1333810T3 (da) Orale selvemulgerende doseringsformuleringer af pyranon-protease-inhibitorer
NL301005I2 (nl) Aliskiren of een farmaceutisch aanvaardbaar zout daarvan; en hydrochloorthiazide of een farmaceutisch aanvaardbaar zout daarvan
CY1118505T1 (el) Στερεη φαρμακευτικη μορφη δοσολογιας περιλαμβανουσα στερεη διασπορα αναστολεα πρωτεασης hiv
NO20031672L (no) Aza- og polyazanaftalenylkarboksamid-derivater anvendbare som HIV-integraseinhibitorer
CY1108522T1 (el) Μεθοδος συνθεσης της περινδοπριλης και των φαρμακευτικως αποδεκτων αλατων της
CY1105237T1 (el) Βελτιωμεναι φαρμακευτικαι διαμορφωσεις πepιλαμβανουσαι ritonavir
ATE516016T1 (de) Selbstemulgierende formulierungen von cetp- hemmern
ATE210441T1 (de) Arzneizusammensetzungen enthaltnd hiv - proteaseinhibitoren
RS50504B (sr) Tečne formulacije
CY1112995T1 (el) Βελτιωμενες φαρμακοτεχνικες μορφες αναστολεων πρωτεασης ηιv
AR032642A1 (es) Composiciones quimioterapicas de paclitaxel en microemulsion con mayor biodisponibilidad oral.
BR0110902A (pt) Inibidores de mmp-9/mmp-2
EE200300027A (et) HIV pöördtranskriptaasi inhibiitoritena kasutatavad tritsüklilised 2-püridooniühendid
AR028537A1 (es) Hidrazidas y alcoxiamidas inhibidoras de la angiogénesis
NO984386L (no) Blandinger omfattende en HIV-protease-inhibitor sÕ som VX 478 og en vannl°selig vitamin E-forbindelse sÕ som vitamin E-TPG'er